Vaxart (NASDAQ:VXRT) Stock Price Crosses Below 200-Day Moving Average - Time to Sell?

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) shares crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.74 and traded as low as $0.69. Vaxart shares last traded at $0.72, with a volume of 848,941 shares trading hands.

Vaxart Price Performance

The company has a market cap of $169.75 million, a price-to-earnings ratio of -1.82 and a beta of 0.82. The firm's fifty day moving average price is $0.71 and its 200-day moving average price is $0.74.

Hedge Funds Weigh In On Vaxart

Hedge funds and other institutional investors have recently modified their holdings of the company. Mesirow Financial Investment Management Inc. boosted its holdings in shares of Vaxart by 100.0% during the third quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company's stock valued at $34,000 after acquiring an additional 20,000 shares during the period. Sequoia Financial Advisors LLC lifted its holdings in Vaxart by 140.9% in the fourth quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company's stock worth $40,000 after purchasing an additional 35,213 shares during the period. Invesco Ltd. lifted its holdings in Vaxart by 48.6% in the fourth quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company's stock worth $50,000 after purchasing an additional 24,803 shares during the period. XTX Topco Ltd lifted its holdings in Vaxart by 869.3% in the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company's stock worth $116,000 after purchasing an additional 122,387 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in Vaxart in the fourth quarter worth about $129,000. Institutional investors and hedge funds own 18.05% of the company's stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.